| scholarly article | Q13442814 |
| P50 | author | Mark Pimentel | Q67172860 |
| P2093 | author name string | Christopher Chang | |
| Mi-Sung Kim | |||
| Gene Kim | |||
| Sharon Kim | |||
| Stacy Weitsman | |||
| Walter Morales | |||
| Andres Ardila Hani | |||
| P2860 | cites work | Sensitivity to rifaximin and rifampicin of Mycobacterium tuberculosis isolated from guinea pigs treated orally with rifaximin. | Q44977196 |
| Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. | Q53867491 | ||
| Interruption of Recurrent Clostridium difficile-Associated Diarrhea Episodes by Serial Therapy with Vancomycin and Rifaximin | Q59567863 | ||
| Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin | Q68987866 | ||
| The specific inhibition of the DNA-directed RNA synthesis by rifamycin | Q69830763 | ||
| Rifaximin systemic absorption in patients with ulcerative colitis | Q74562312 | ||
| Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin | Q77687423 | ||
| Rifaximin intake leads to emergence of rifampin-resistant staphylococci | Q82442238 | ||
| Review of rifaximin as treatment for SIBO and IBS | Q83395678 | ||
| Rifaximin for maintenance therapy in antibiotic-dependent pouchitis | Q21261868 | ||
| Small intestinal bacterial overgrowth in patients with irritable bowel syndrome | Q24674609 | ||
| Rifaximin therapy for patients with irritable bowel syndrome without constipation | Q28302405 | ||
| Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis | Q28379624 | ||
| The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome | Q34248518 | ||
| In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species | Q34509301 | ||
| Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis | Q34525343 | ||
| Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci | Q34552369 | ||
| Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. | Q34722938 | ||
| Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative | Q34729751 | ||
| Detection of nucleotide variability in rpoB in both rifampin-sensitive and rifampin-resistant strains of Chlamydia trachomatis | Q35102788 | ||
| Rifaximin: in vitro and in vivo antibacterial activity--a review | Q36108484 | ||
| Management of colonic diverticular disease | Q36404937 | ||
| Microbial flora in NSAID-induced intestinal damage: a role for antibiotics? | Q36404975 | ||
| Resistance to rifampicin: at the crossroads between ecological, genomic and medical concerns | Q37698796 | ||
| Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects | Q37874146 | ||
| Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus | Q39559116 | ||
| Optimization of Real-Time PCR Assay for Rapid and Sensitive Detection of Eubacterial 16S Ribosomal DNA in Platelet Concentrates | Q40133289 | ||
| Rifaximin in the treatment of inflammatory bowel disease | Q43010964 | ||
| A new rat model links two contemporary theories in irritable bowel syndrome | Q43353492 | ||
| Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders | Q44662618 | ||
| P433 | issue | 6 | |
| P921 | main subject | rifaximin | Q416073 |
| P304 | page(s) | 1676-1682 | |
| P577 | publication date | 2013-04-16 | |
| P1433 | published in | Digestive Diseases and Sciences | Q15716711 |
| P1476 | title | The effect of rifaximin on gut flora and Staphylococcus resistance. | |
| P478 | volume | 58 |
| Q38684559 | A meta-analysis of the use of rifaximin to prevent travellers' diarrhoea. |
| Q36970524 | Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome |
| Q41990739 | Emergence of rifampin-resistant staphylococci after rifaximin administration in cirrhotic patients |
| Q39455595 | Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation |
| Q89565726 | Microbiome and Its Role in Irritable Bowel Syndrome |
| Q46302916 | Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome |
| Q35855732 | Review article: the antimicrobial effects of rifaximin on the gut microbiota |
| Q36009729 | Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation. |
| Q98177469 | Selective Regional Alteration of the Gut Microbiota by Diet and Antibiotics |
| Q57070200 | Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin |
| Q64276819 | Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease |
| Q53781806 | The effect of sub-inhibitory concentrations of rifaximin on urease production and on other virulence factors expressed by Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus. |
Search more.